Stock comparison
Haemonetics
Pharming Group N.V.
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
PHAR
Pharming Group N.V.
Market cap
$889.88M
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | PHAR | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 37D | HAE |
| Benjamin Graham | 85A | 67D | HAE |
| Philip Fisher | 60C | 43D | HAE |
| Peter Lynch | 54C | 25F | HAE |
| Joel Greenblatt | 31F | 44D | PHAR |
| Charlie Munger | 54D | 34F | HAE |
| Terry Smith | 55D | 41D | HAE |
Side-by-side metrics
| Metric | HAE | PHAR |
|---|---|---|
| Market cap | $2.98B | $889.88M |
| P/E (TTM) | 24.8x | 77.6x |
| EV/EBIT | 14.1x | 50.7x |
| ROIC (TTM) | 8.37% | 3.76% |
| Gross margin | 55.74% | 88.12% |
| Net margin | 7.29% | 3.37% |
| Revenue CAGR 5y | 7.65% | 17.35% |
| EPS CAGR 5y | 24.62% | -33.13% |
| Debt / Equity | 1.5x | 0.4x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs -33.13%+174%
- EV/EBIT14.1xvs 50.7x+72%
- Market cap$2.98Bvs $889.88M+70%
- P/E (TTM)24.8xvs 77.6x+68%
PHAR leads on
- Debt / Equity0.4xvs 1.5x+72%
- Revenue CAGR 5y17.35%vs 7.65%+56%
- Gross margin88.12%vs 55.74%+37%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.